- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03038776
Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)
A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Because antibody responses to experimental H7 vaccine have been low even with high antigen doses, there is a need to find ways to enhance the effectiveness of H7 vaccines. Protein Sciences Corporation (PSC) produces an FDA approved seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutinin proteins (HA) which are full length uncleaved glycoproteins (rHA0) produced using baculovirus expression vectors in cultured insect cells grown in serum-free media (FluBlok®). The mechanism of action of FluBlok is the same as that of traditional inactivated seasonal influenza vaccines.
PanBlok H7 is a pandemic influenza vaccine produced by PSC in the same way as Flublok but it is directed against H7 rather than seasonal influenza virus strains. The vaccine candidate consists of a full-length recombinant monovalent hemagglutinin (rHA) derived from H7N9 virus, in a sterile solution for intramuscular injection. PanBlok H7 rHA is manufactured using the same production process as previously used for Panblok H1/2009pdm ("swine flu") and Panblok H5 pandemic vaccines, both of which vaccines have been previously successfully trialled by us in clinical protocols, FLU005 and FLU003. In both these trials the Panblok antigen was combined with Advax adjuvant formulations. In the FLU005 trial of Panblok H1N1/2009pdm vaccine, the inclusion of Advax adjuvant doubled the seroconversion rate of the vaccine and provided major antigen-sparing effects (Gordon et al, 2012). Whilst the FLU003 trial is ongoing, preliminary data again shows the importance of the Advax adjuvants to vaccine effectiveness. This provides a strong rationale for inclusion of Advax adjuvants in the Panblok H7 vaccine.
It has also been recently recognised that at least one of the reasons for the low immunogenicity of H7 vaccines in human trials to date is that the H7 antigen from this virus contains a T-cell regulatory epitope (Tregitope) in the HA stem region which suppresses the immune response to the vaccine. It was recently demonstrated in humanised animal studies undertaken by collaborators in Japan that removing this Tregitope by modifying 3 amino acids in the H7 stem was able to significantly increase the ability of the H7 vaccine to induce antibody production by human immune cells. This trial will provide the first opportunity to confirm this approach is able to enhance the immunogenicity of H7 in humans, which if confirmed would represent a major breakthough in pandemic influenza vaccine design.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5042
- Flinders University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Age 18 years or over
- Able to provide written informed consent
- Willing and able to comply with the protocol for the duration of the study
Exclusion Criteria:
- History of serious vaccine allergy*
- History of vasculitis, Wegener's granulomatosis, narcolepsy, Guillain Barre, SLE or other systemic autoimmune disease that in the opinion of the investigator would make the vaccine contraindicated
- History of chronic liver disease or liver transaminases elevated more than 3xULN
- Women of childbearing potential, unless using a reliable and appropriate contraceptive method, specifically oral contraceptive pill, IUD or mechanical barrier device.
- Pregnant or lactating women.
- Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.
Receipt of another investigational agent within 28 days preceding initiation of treatment.
- Individuals who have a past history of potential vaccine reactions will be assessed by the investigator, who will decide whether any past potential vaccine-related side are sufficiently minimal to allow vaccine administration to proceed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
|
Avian H7N9 influenza vaccine
Other Names:
|
EXPERIMENTAL: 2
Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
|
Avian H7N9 influenza vaccine
Other Names:
|
EXPERIMENTAL: 3
Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
|
Avian H7N9 influenza vaccine
Other Names:
|
EXPERIMENTAL: 4
Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
|
Avian H7N9 influenza vaccine
Other Names:
|
EXPERIMENTAL: 5
Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
|
Avian H7N9 influenza vaccine
Other Names:
|
EXPERIMENTAL: 6
Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
|
Avian H7N9 influenza vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seroconversion
Time Frame: 1 month post immunization
|
1 month post immunization
|
Seroprotection
Time Frame: 1 month post immunization
|
1 month post immunization
|
Fold rise in geometric mean titer
Time Frame: 1 month post immunization
|
1 month post immunization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Frequency and severity of adverse events
Time Frame: 12 months post immunization
|
Frequency and severity of adverse events
|
12 months post immunization
|
T cell response
Time Frame: 1 month post-immunization
|
Frequency of influenza specific T cells
|
1 month post-immunization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dimitar Sajkov, MD, PhD, Flinders University/ARASMI
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLU007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza, Avian
-
Mahidol UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Southeast Asia...Completed
-
Novartis VaccinesCompletedProphylaxis of Avian InfluenzaFinland
-
Novartis VaccinesCompletedProphylaxis of Avian Influenza VaccineUnited Kingdom
-
Mahidol UniversityCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
SeqirusBiomedical Advanced Research and Development AuthorityCompleted
-
Novartis VaccinesCompleted
-
Mahidol UniversityWorld Health Organization; The Government Pharmaceutical OrganizationCompletedEvaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 VaccineAvian InfluenzaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Recombinant influenza hemagglutinin
-
Protein Sciences CorporationCompleted
-
Protein Sciences CorporationCompleted
-
VaxInnate CorporationUnknown
-
Protein Sciences CorporationCompleted
-
Protein Sciences CorporationCompleted
-
Laboratorios LiomontEPIC Research CRO; ILS Clinical Research; Q Square SolutionsCompleted
-
Vaxine Pty LtdAustralian Respiratory and Sleep Medicine Institute; Flinders UniversityCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza | Influenza ImmunizationUnited States
-
Protein Sciences CorporationCompleted
-
SanofiProtein Sciences CorporationCompletedInfluenzaUnited States